CA-ALKIRA
22.11.2021 10:02:09 CET | Business Wire | Press release
Alkira Inc. has appointed Exclusive Networks, a global trusted cybersecurity specialist for digital infrastructure, as a distributor for its cloud networking as-a-service platform (CNaaS).
The deal makes Alkira’s CNaaS platform Cloud Services Exchange (CSX) available through Exclusive’s global partner ecosystem spanning 40 countries across five continents. It also underlines Exclusive’s commitment to growing its cloud portfolio in a market estimated by IDC to be on track for $1.3 trillion by 20251 .
Exclusive Networks (EXN), which posted gross sales of €2.9 billion in 2020, completed a successful Initial Public Offering and listing on Euronext Paris in September this year. The company has partnerships with some of the world’s largest and most successful cybersecurity, networking and cloud infrastructure vendors, including Fortinet, Nutanix, Palo Alto Networks, Rubrik and Sentinel One. It provides cybersecurity platforms, cloud solutions and associated value-add professional services through an extensive global partner network of specialist resellers, MSPs, CSPs, telcos and systems integrators.
Alkira has appointed Paul Couturier as Senior VP International to spearhead its expansion in the EMEA and APAC regions. Couturier is an IT industry veteran who has previously held senior management roles growing international markets for Efficient Networks, TippingPoint, Cyan, LightCyber and Palo Alto Networks. In his latest role, he managed IntSights from its European debut to its acquisition by Rapid 7.
Amir Khan, Co-Founder and Chief Executive Officer of Alkira, said: “Our vision is to simplify networking in the cloud era. As the CNaaS pioneer, Alkira has eliminated the complexities and costs of building and operating networks and seamlessly integrated cloud, multi-cloud and legacy systems – no hardware, no data center, no need to ship anything. Exclusive Networks is an ideal partner for Alkira, not only because it provides us with access to their first-class global network, but because we have a shared vision of an as-a-service future.”
Andy Travers, Executive Vice President, Worldwide Sales and Marketing for Exclusive Networks, said: “Our success has been built on bringing together best in class cybersecurity, networking and automation solutions. In the cloud era, the challenge for customers is how to integrate and manage these resources in an increasingly complex environment, while controlling costs and moving the business forward. With nothing more than a few mouse clicks, Alkira’s CNaaS enables secure hybrid cloud and multi-cloud networks to be set up in hours rather than months, and puts customers, not the big cloud providers, in the driver’s seat.
“Migration of enterprise applications to the cloud is set to double in the next two years, according to Gartner2 , so it seems inevitable that networking infrastructure will follow the same trend. Just as Alkira’s founders pioneered the SD-WAN market, we now believe they are showing the way in cloud networking.”
Alkira’s CNaaS platform simplifies provisioning, connectivity and end-to-end management of networks across cloud environments, including the integration of firewalls, IPS/IDS, and load balancers, as well as enhancing the capabilities of legacy SD-WAN solutions. It enables a flexible, unified approach to secure, high-performance networking in which customers only pay for the capacity they use, and the network automatically scales to meet changing patterns of usage and demand.
About Alkira
Alkira® developed the Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira CSX seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of integrated solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.alkira.com or follow us @AlkiraNet
(Alkira® and Alkira Cloud Services Exchange® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.)
About Exclusive Networks
Exclusive Networks is a global trusted cybersecurity specialist for digital infrastructure helping to drive the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models. The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to deliver partner value. With offices in 40 countries and the ability to service customers in over 150 countries across five continents, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. Learn more at www.exclusive-networks.com or follow us @EXN_Networks
1
IDC Forecasts Worldwide "Whole Cloud" Spending to Reach $1.3 Trillion by 2025
2
Market Guide to Cloud Networking Software, Gartner, May 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom